Nodular Basal Cell Carcinoma Clinical Trial
Official title:
Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Nodular Basal Cell Carcinoma in Asian: A Prospective, Randomized Study With 12 Months Follow-up
Verified date | December 2013 |
Source | Dong-A University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Institutional Review Board |
Study type | Interventional |
Topical photodynamic therapy with methyl-aminolaevulinate (MAL-PDT) has been introduced as an alternatively attractive procedure for BCC. Er:YAG ablative fractional laser (AFL) treatment removes the stratum corneum to increase MAL uptake and may improve efficacy. However, no studies have directly compared the efficacy of Er:YAG AFL-PDT and MAL-PDT in treating nodular BCC in Asians.
Status | Completed |
Enrollment | 34 |
Est. completion date | September 2013 |
Est. primary completion date | February 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 38 Years to 78 Years |
Eligibility |
Inclusion Criteria: - patient's request for alternative treatment due to the lower cosmetic outcomes of surgery - difficulty to surgical excision due to bleeding abnormalities or cardiac problems Exclusion Criteria: - patients with more than 5 eligible lesions - lesions deeper than 2mm in depth - lesions located in the midface region, nose, orbital areas, and ears - lesions with a longest diameter of less than 6 mm or more than 15mm - infiltrative BCC - morpheaform BCC - known allergies to the MAL cream or lidocaine - pregnancy - lactation - any active systemic infectious disease - immunosuppressive treatment - personal history of malignant melanoma - tendency towards melasma or keloid formation - prior treatment of the lesions within 4 weeks - any indication of poor compliance |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Dong-A University | Busan | Seo-gu |
Lead Sponsor | Collaborator |
---|---|
Dong-A University |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Difference of the recurrence rates between Er:YAG AFL-PDT and MAL-PDT | In all cases of complete response, the patients were reviewed at 12 months to check for recurrence. Recurrence was assessed by inspection, dermoscopy, photography, palpation, and histologic findings. | recurrence rates were evaluated at 12 months after the last treatment. | No |
Other | Difference of the safety between Er:YAG AFL-PDT and MAL-PDT | Adverse events reported by the patient were noted at each follow-up visit, including severity, duration, and need for additional treatment. The severity of the adverse event was assessed as follows: mild (transient and easily tolerated); moderate (caused the patient discomfort and interrupted usual activities); and severe (caused considerable interference with usual activities and may have been incapacitating or life threatening). All adverse events due to PDT were described as phototoxic reactions (i.e. erythema, postinflammatory hyperpigmentation, edema, itching, oozing, bleeding, etc.). |
Safety assessments were performed at the end of the 3-hour cream application; after the illumination during each treatment session; and at 1 week, 3 months, and 12 months after the last treatment | Yes |
Primary | Difference the efficacy between Er:YAG AFL-PDT and MAL-PDT | Lesion responses were classified as either a complete response (complete disappearance of the lesion) or a non-complete response (incomplete disappearance) | Efficacy was evaluated at 3 months and 12 months after treatment | No |
Secondary | Difference of the cosmetic outcomes between Er:YAG AFL-PDT and MAL-PDT treatment | I was graded using a 4-point scale: excellent (only slight occurrence of redness or change in pigmentation), good (moderate redness or change in pigmentation), fair (slight to moderate scarring, atrophy, or induration), or poor (extensive scarring, atrophy, or induration) | Cosmetic outcome was assessed by each investigator for all lesions that achieved a complete response at 3 or 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04552990 -
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02270645 -
Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser
|
N/A | |
Recruiting |
NCT05157763 -
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02242929 -
Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma
|
Phase 3 | |
Terminated |
NCT01808950 -
Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04744935 -
Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma
|
N/A | |
Completed |
NCT04470726 -
Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma
|
Phase 1/Phase 2 |